The kidneys are critical organs in peptide receptor radiation therapy (PRRT). Renal function
loss may become apparent many years after PRRT. We analyzed the time course of decline …

Purpose Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumours with 90
Y-DOTATOC and 177 Lu-DOTATATE is promising. The kidney is the critical organ and …

Purpose Peptide receptor radionuclide therapy (PRRT) has become an important treatment
option in the management of advanced neuroendocrine tumours. Long-lasting responses …

Purpose Renal radiation during peptide receptor radionuclide therapy (PRRT) may result in
glomerular damage, a potential reduction of glomerular filtration rate (GFR) and ultimately …

Abstract [Yttrium-90-DOTA-Tyr 3]-octreotide (DOTATOC) and [177 Lu-DOTA-Tyr 3-Thr 8]-
octreotide (DOTATATE) are used for peptide receptor-mediated radionuclide therapy …

Purpose Peptide receptor radionuclide therapy (PRRT) with 177 Lu-octreotate is commonly
administered at empiric, fixed amounts of injected radioactivity (IA). This results in highly …

Purpose Peptide receptor radionuclide therapy (PRRT) is used in tumours expressing type 2
somatostatin receptors (sst 2), mainly neuroendocrine. The aim of this prospective phase I-II …

Purpose After peptide receptor radionuclide therapy (PRRT), renal toxicity may occur,
particular in PRRT with 90 Y-labelled somatostatin analogues. Risk factors have been …

Purpose Peptide receptor radionuclide therapy (PRRT) is mostly administered using a fixed
injected activity (IA) per cycle. This empiric regime results in highly variable absorbed doses …

Kidney dosimetry in 177 Lu and 90 Y PRRT requires 3 to 6 whole-body/SPECT scans to
extrapolate the peptide kinetics, and it is considered time and resource consuming. We …